Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ezetimibe/simvastatin switch versus atorvastatin dose doubling in high-risk primary hypercholesterolemia
2008-005002-40Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Sep 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hypercholesterolemia comparing Switch to ezetimibe/simvastatin with Atorvastatin dose doubling (2 arms). Primary endpoint: Percent change from baseline in LDL cholesterol at endpoint. Started Sep 2008; status: completed.
02
Drugs
ezetimibesimvastatinatorvastatin
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on 2008-005002-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-005002-40.